Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 120
- Registration Number
- NCT06594744
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06566794
- Locations
- 🇫🇮
Department of Clinical Pharmacology, Helsinki, Finland
The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT06470386
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 474
- Registration Number
- NCT06449339
- Locations
- 🇭🇰
Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Arab Contractors Medical Centre
- Target Recruit Count
- 150
- Registration Number
- NCT06304896
- Locations
- 🇪🇬
Arab Contractors Medical Centre, Cairo, Egypt
Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 70
- Registration Number
- NCT06108518
Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 180
- Registration Number
- NCT06041932
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences., New Delhi, Delhi, India
Determination of Drug Levels for Pharmacotherapy of Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- University Hospital Ostrava
- Target Recruit Count
- 100
- Registration Number
- NCT06035978
- Locations
- 🇨🇿
University Hospital Ostrava, Ostrava, Czech Republic, Czechia
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 2540
- Registration Number
- NCT05931276
- Locations
- 🇺🇸
Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States
🇺🇸VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸VA NY Harbor Healthcare System, New York, NY, New York, New York, United States
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 1200
- Registration Number
- NCT05872698
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.